Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks

Stefanutti, C.; Lanti, Alessandro; Giacomo, S. Di; Mareri, Maura; Lorenzo, F. De; A, Landolfo; Isacchi, G

doi:10.1016/j.transci.2004.01.010

Cited by 47 publications

(42 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LA is efficacious, tolerable and safe for children with severe FH and may be commenced after the age of 5 years [8,152,158,159], or earlier in exceptional circumstances. While lower body weight is a recognised risk factor for complications, successful outcomes have been reported with LA in very young children with homozygous FH [152,159,160].…”

Section: Lipoprotein Apheresis and Other Invasive Therapiesmentioning

confidence: 99%

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts

Gidding

Wierzbicki

et al. 2014

International Journal of Cardiology

329

200

View full text Add to dashboard Cite

Section: Lipoprotein Apheresis and Other Invasive Therapiesmentioning

confidence: 99%

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts

Gidding

Wierzbicki

et al. 2014

International Journal of Cardiology

329

200

View full text Add to dashboard Cite

“…The aim of this study was to evaluate the data collected at that time with regard to therapeutic pediatric apheresis, including information regarding technological applications, patient management, complications, and risks as well as aspects such as anticoagulation, vascular access, extracorporeal volume, adverse effects, and treatment compliance [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

The Italian registry of pediatric therapeutic apheresis: A report on activity during 2005

Silvestro¹,

Tison²,

Vicarioto³

et al. 2008

J of Clinical Apheresis

View full text Add to dashboard Cite

The results of the 2005 Survey of the Italian Society for Apheresis and Cell Manipulation (SIdEM) reporting on the pediatric procedures carried out in 18 Italian Apheresis Units are presented here. Utilizing a standardized questionnaire, the survey collected data on techniques, types of blood separators, clinical indications, and adverse events. A total of 1,693 apheresis procedures were carried out in 355 pediatric patients: 219 plasma-exchange, 291 peripheral blood stem cell collections, 791 extracorporeal photochemotherapy (ECP), 265 LDL-apheresis, 71 erythro-exchange, 9 cytoreductive apheresis, 47 immunoadsorption sessions. Adverse events were registered in 94 procedures (5.6%), most of which of mild entity, e.g., insufficient flow rate (50.0%) and symptomatic hypocalcemia (24.4%). Our data indicate that all types of apheresis procedures can be safely carried out in children. ECP, utilized primarily for the treatment of graft versus host disease (GvHD) and rejection of solid organ transplantation, are burgeoning procedures in pediatric patients, whereas plasma exchange, which is a common treatment in adults, is infrequently utilized in pediatric medicine.

show abstract

“…In general, when the volume of the extracorporeal circulation is lower than 15% of the patient's total blood volume, there are no signifi cant side effects [13]. In our patient, the volume of the extracorporeal circulation was about 15% of the patient's total blood volume.…”

Section: Discussionmentioning

confidence: 52%

“…The use of therapeutic apheresis in pediatric patients is limited because of lack of cooperation, the relatively large extracorporeal volume, and the diffi culties in adequate vascular access [13]. In general, when the volume of the extracorporeal circulation is lower than 15% of the patient's total blood volume, there are no signifi cant side effects [13].…”

Section: Discussionmentioning

confidence: 99%

Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis

et al. 2009

View full text Add to dashboard Cite

Focal segmental glomerulosclerosis (FSGS) often leads to refractory nephrotic syndrome (NS). A high level of low-density lipoprotein (LDL) is a risk factor for the progression of NS. An 8-year-old girl presented with severe proteinuria refractory to steroid therapy. She was diagnosed with non-IgA diffuse mesangial proliferative glomerulonephritis. Oral prednisolone, methylprednisolone (mPL) pulse therapy, and cyclosporine and cyclophosphamide therapy failed to achieve remission. Follow-up renal biopsy revealed FSGS. Her serum level of LDL was high, and LDL-apheresis (LDL-A) was performed five times, followed by mPL pulse therapy. Urinary protein decreased from 2-4 g x day(-) to 0.5-1.0 g x day(-). LDL-A may be beneficial in the treatment of multidrug-resistant FSGS.

show abstract

Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks

Cited by 47 publications

References 13 publications

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

The Italian registry of pediatric therapeutic apheresis: A report on activity during 2005

Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis

Contact Info

Product

Resources

About